



Order: 999999-9999



Client #: 999999

Doctor: Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

Patient: Sample Patient

Id: 999999

Age: 32 DOB:

Sex: Female

Sample Collection

Date/Time

Date Collected

01/11/2023

Date Received

01/13/2023

Date Reported


01/23/2023

Specimens Collected


3

### Microbiome Abundance and Diversity Summary

The abundance and diversity of gastrointestinal bacteria provide an indication of gastrointestinal health, and gut microbial imbalances can contribute to dysbiosis and other chronic disease states. The GI360™ Microbiome Profile is a gut microbiota DNA analysis tool that identifies and characterizes more than 45 targeted analytes across six Phyla using PCR and compares the patient results to a characterized normobiotic reference population. The web chart illustrates the degree to which an individual's microbiome profile deviates from normobiosis.



#### LEGEND




The web image shows the relative diversity and balance among bacteria belonging to the six primary Phyla. The white shaded area represents the patient's results compared to a normobiotic reference population. The center of the web represents less abundance while the outer edges represent more than normobiotic.

### Dysbiosis and Diversity Index

These indexes are calculated from the results of the Microbiome Profile, with scores ranging from 1 to 5, and do not include consideration of dysbiotic and pathogenic bacteria, yeast, parasites and viruses that may be reported in subsequent sections of the GI360™ test.

The Dysbiosis Index the (DI) is calculated strictly from the results of the Microbiome Profile, with scores from 1 to 5. A DI score above 2 indicates dysbiosis; a microbiota profile that differs from the defined normobiotic reference population. The higher the DI above 2, the more the sample deviates from the normobiotic profile. The dysbiosis test and DI does not include consideration of dysbiotic and pathogenic bacteria, yeast, parasites and viruses that may be reported in subsequent sections of the GI360™ test.

A diversity score of 3 indicates an expected amount of diversity, with 4 & 5 indicating an increased distribution of bacteria based on the number of different species and their abundance in the sample, calculated based on Shannon's diversity index. Scores of 1 or 2 indicate less diversity than the defined normobiotic reference population.



Dysbiosis Index



Diversity Score



### Key Findings

Butyrate producing bacteria	<input checked="" type="checkbox"/>	<i>Citrobacter freundii</i> complex, Cultured
Gut barrier protective bacteria	<input checked="" type="checkbox"/>	<i>Enterobacter cloacae</i> complex, Cultured
Gut intestinal health marker	<input checked="" type="checkbox"/>	<i>Klebsiella pneumoniae</i> , Cultured
Pro-inflammatory bacteria	<input checked="" type="checkbox"/>	<i>Candida lusitanae</i> , Cultured
Gut barrier protective bacteria vs. opportunistic bacteria	<input checked="" type="checkbox"/>	

= Expected     = Imbalanced



# Microbiome Bacterial Abundance; Multiplex PCR



**Order:** 999999-9999



**Client #:** 999999

**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

**Patient:** Sample Patient

**Id:** 999999

**Age:** 32 **DOB:**

**Sex:** Female

**Sample Collection**

**Date/Time**

**Date Collected**

01/11/2023

**Date Received**

01/13/2023


**Date Reported**

01/23/2023


**Specimens Collected**

3

## LEGEND



Results are graphed as deviations from a normobiotic population. Normobiosis or a normobiotic state characterizes a composition of the microbiota profile in which microorganisms with potential health benefits predominate in abundance and diversity over potentially harmful ones.



### Notes:

The gray-shaded area of the bar graph represents reference values outside the reporting limits for this test.

\*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.

Methodology: Multiplex PCR



**Order:** 999999-9999



**Client #:** 999999

**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

**Patient:** Sample Patient

**Id:** 999999

**Age:** 32 **DOB:**

**Sex:** Female

**Sample Collection**

**Date/Time**

**Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**

01/23/2023

**Specimens Collected**

3

Firmicutes	Result	-3	-2	-1	0	+1	+2	+3	Reference Interval
Clostridia Class	0				▲				0
<i>Clostridium methylpentosum</i>	0				▲				0
<i>Clostridium</i> L2-50	0				▲				0
<i>Coprobacillus cateniformis</i>	0				▲				0
<i>Dialister invisus</i>	0				▲				0
<i>Dialister invisus</i> & <i>Megasphaera micronuciformis</i>	0				▲				0
<i>Dorea</i> spp.	-1			▲					0
<i>Eubacterium bifforme</i>	0				▲				0
<i>Eubacterium hallii</i>	-2	▲							0
<i>Eubacterium rectale</i>	0				▲				0
<i>Eubacterium siraeum</i>	0				▲				0
<i>Faecalibacterium prausnitzii</i>	0				▲				0
Lachnospiraceae	0				▲				0
<i>Lactobacillus ruminis</i> & <i>Pediococcus acidilactici</i>	0				▲				0
<i>Lactobacillus</i> family	-1			▲					0
<i>Phascolarctobacterium</i> spp.	0				▲				0
<i>Ruminococcus albus</i> & <i>R. bromii</i>	0				▲				0
<i>Ruminococcus gnavus</i>	0				▲				0
<i>Streptococcus agalactiae</i> & <i>Eubacterium rectale</i>	0				▲				0
<i>Streptococcus salivarius</i> ssp. <i>thermophilus</i> & <i>S. sanguinis</i>	0				▲				0

**Notes:**

The gray-shaded area of the bar graph represents reference values outside the reporting limits for this test.

\*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.

Methodology: Multiplex PCR



**Order:** 999999-9999



**Client #:** 999999

**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

**Patient:** Sample Patient

**Id:** 999999

**Age:** 32 **DOB:**

**Sex:** Female

**Sample Collection**

**Date/Time**

**Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**

01/23/2023

**Specimens Collected**


3

Firmicutes	Result	-3	-2	-1	0	+1	+2	+3	Reference Interval
<i>Streptococcus salivarius</i> ssp. <i>thermophilus</i>	0				▲				0
<i>Streptococcus</i> spp.	0				▲				0
<i>Veillonella</i> spp.	0				▲				0
Proteobacteria	Result	-3	-2	-1	0	+1	+2	+3	Reference Interval
Proteobacteria	0				▲				0
<i>Enterobacteriaceae</i>	+2						▲		0
<i>Escherichia</i> spp.	0				▲				0
<i>Acinetobacter junii</i>	0				▲				0
Tenericutes	Result	-3	-2	-1	0	+1	+2	+3	Reference Interval
<i>Mycoplasma hominis</i>	0				▲				0
Verrucomicrobia	Result	-3	-2	-1	0	+1	+2	+3	Reference Interval
<i>Akkermansia muciniphila</i>	0				▲				0



## Microbiome Abundance Information:

- The GI360™ Microbiome Profile is a focused gut microbiota DNA analysis tool that identifies more than 45 targeted analytes across six phyla using a CE-marked multiplex PCR system. Patient results are compared to a highly defined normobiotic reference population (n > 1,100). The white shadowed web plot within the hexagonal diagram illustrates the degree to which an individual's microbiome profile deviates from normobiosis. The center of the diagram represents less bacterial abundance while the outer edges represent greater than normobiosis. Deviation from a hexagon-shaped plot indicates variant diversity of the microbial community. Key findings for patient's microbiome profile are summarized in the table below the diagram, and detailed results for all of the analytes are presented on the next 3 pages of the report. Detailed results for the specific bacteria are reported as -3 to +3 standard deviations, as compared to the normobiotic reference population.



### Notes:

The gray-shaded area of the bar graph represents reference values outside the reporting limits for this test.

\*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.

Methodology: Multiplex PCR



Order: 999999-9999



Client #: 999999

Doctor: Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

Patient: Sample Patient

Id: 999999

Age: 32 DOB:

Sex: Female

Sample Collection

Date/Time

Date Collected

01/11/2023

Date Received

01/13/2023

Date Reported

01/23/2023

Specimens Collected

3

Viruses	Result	
Adenovirus F40/41	Negative	<input checked="" type="checkbox"/>
Norovirus GI/GII	Negative	<input checked="" type="checkbox"/>
Rotavirus A	Negative	<input checked="" type="checkbox"/>

Pathogenic Bacteria	Result	
<i>Campylobacter</i> ( <i>C. jejuni</i> , <i>C. coli</i> and <i>C. lari</i> )	Negative	<input checked="" type="checkbox"/>
<i>Clostridioides difficile</i> (Toxin A/B)	Negative	<input checked="" type="checkbox"/>
<i>Escherichia coli</i> O157	Negative	<input checked="" type="checkbox"/>
Enterotoxigenic <i>Escherichia coli</i> (ETEC) It/st	Negative	<input checked="" type="checkbox"/>
<i>Salmonella</i> spp.	Negative	<input checked="" type="checkbox"/>
Shiga-like toxin-producing <i>Escherichia coli</i> (STEC) stx1/stx2	Negative	<input checked="" type="checkbox"/>
<i>Shigella</i> ( <i>S. boydii</i> , <i>S. sonnei</i> , <i>S. flexneri</i> & <i>S. dysenteriae</i> )	Negative	<input checked="" type="checkbox"/>
<i>Vibrio cholerae</i>	Negative	<input checked="" type="checkbox"/>

Parasites	Result	
<i>Cryptosporidium</i> ( <i>C. parvum</i> and <i>C. hominis</i> )	Negative	<input checked="" type="checkbox"/>
<i>Entamoeba histolytica</i>	Negative	<input checked="" type="checkbox"/>
<i>Giardia duodenalis</i> (AKA <i>intestinalis</i> & <i>lamblia</i> )	Negative	<input checked="" type="checkbox"/>

Notes:

Methodology: Multiplex PCR





Order: 999999-9999



Client #: 999999

Doctor: Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

Patient: Sample Patient

Id: 999999

Age: 32 DOB:

Sex: Female

Sample Collection

Date/Time

Date Collected

01/11/2023

Date Received

01/13/2023

Date Reported

01/23/2023

Specimens Collected

3

Protozoa

Result

<i>Balantidium coli</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Blastocystis spp.</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Chilomastix mesnili</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Dientamoeba fragilis</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Endolimax nana</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Entamoeba coli</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Entamoeba hartmanni</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Entamoeba histolytica/Entamoeba dispar</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Entamoeba polecki</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Enteromonas hominis</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Giardia duodenalis</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Iodamoeba bütschlii</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Isospora belli</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Pentatrichomonas hominis</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Retortamonas intestinalis</i>	Not Detected	<input checked="" type="checkbox"/>

Cestodes - Tapeworms

Result

<i>Diphyllobothrium latum</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Dipylidium caninum</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Hymenolepis diminuta</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Hymenolepis nana</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Taenia</i>	Not Detected	<input checked="" type="checkbox"/>

Trematodes - Flukes

Result

<i>Clonorchis sinensis</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Fasciola hepatica/Fasciolopsis buski</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Heterophyes heterophyes</i>	Not Detected	<input checked="" type="checkbox"/>
<i>Paragonimus westermani</i>	Not Detected	<input checked="" type="checkbox"/>

Nematodes - Roundworms

Result

<i>Ascaris lumbricoides</i>	Not Detected	<input checked="" type="checkbox"/>
-----------------------------	--------------	-------------------------------------

Notes:

Methodology: Microscopy



Order: 999999-9999



Client #: 999999

Doctor: Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

Patient: Sample Patient

Id: 999999

Age: 32 DOB:

Sex: Female

Sample Collection

Date/Time

Date Collected

01/11/2023

Date Received

01/13/2023

Date Reported

01/23/2023

Specimens Collected

3

Nematodes - Roundworms

Result

Capillaria hepatica	Not Detected	<input checked="" type="checkbox"/>
Capillaria philippinensis	Not Detected	<input checked="" type="checkbox"/>
Enterobius vermicularis	Not Detected	<input checked="" type="checkbox"/>
Hookworm	Not Detected	<input checked="" type="checkbox"/>
Strongyloides stercoralis	Not Detected	<input checked="" type="checkbox"/>
Trichuris trichiura	Not Detected	<input checked="" type="checkbox"/>

Other Markers

Result

Reference Interval

Yeast	Rare	<input checked="" type="checkbox"/>	Not Detected – Rare
RBC	Not Detected	<input checked="" type="checkbox"/>	Not Detected – Rare
WBC	Not Detected	<input checked="" type="checkbox"/>	Not Detected – Rare
Muscle fibers	Not Detected	<input checked="" type="checkbox"/>	Not Detected – Rare
Vegetable fibers	Rare	<input checked="" type="checkbox"/>	Not Detected – Few
Charcot-Leyden Crystals	Not Detected	<input checked="" type="checkbox"/>	Not Detected
Pollen	Not Detected	<input checked="" type="checkbox"/>	Not Detected

Macroscopic Appearance

Result

Reference Interval

Color	Brown	<input checked="" type="checkbox"/>	Brown
Consistency	Soft	<input checked="" type="checkbox"/>	Soft
Mucus	Negative	<input checked="" type="checkbox"/>	Negative



Parasitology Information:

- This test is not designed to detect *Cyclospora cayetanensis* or *Microsporidia* spp.
- Intestinal parasites are abnormal inhabitants of the gastrointestinal tract that have the potential to cause damage to their host. The presence of any parasite within the intestine generally confirms that the patient has acquired the organism through fecal-oral contamination. Damage to the host includes parasitic burden, migration, blockage and pressure. Immunologic inflammation, hypersensitivity reactions and cytotoxicity also play a large role in the morbidity of these diseases. The infective dose often relates to severity of the disease and repeat encounters can be additive.
- There are two main classes of intestinal parasites, they include protozoa and helminths. The protozoa typically have two stages; the trophozoite stage that is the metabolically active, invasive stage and the cyst stage, which is the vegetative inactive form resistant to unfavorable environmental conditions outside the human host. Helminths are large, multicellular organisms. Like protozoa, helminths can be either free-living or parasitic in nature. In their adult form, helminths cannot multiply in humans.

Notes:

Methodology: Microscopy, Macroscopic Observation



**Order:** 999999-9999



**Client #:** 999999

**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

**Patient:** Sample Patient

**Id:** 999999

**Age:** 32 **DOB:**

**Sex:** Female

**Sample Collection**

**Date/Time**

**Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**

01/23/2023


**Specimens Collected**

3



**Parasitology Information:**

- In general, acute manifestations of parasitic infection may involve diarrhea with or without mucus and or blood, fever, nausea, or abdominal pain. However these symptoms do not always occur. Consequently, parasitic infections may not be diagnosed or eradicated. If left untreated, chronic parasitic infections can cause damage to the intestinal lining and can be an unsuspected cause of illness and fatigue. Chronic parasitic infections can also be associated with increased intestinal permeability, irritable bowel syndrome, irregular bowel movements, malabsorption, gastritis or indigestion, skin disorders, joint pain, allergic reactions, and decreased immune function.
- In some instances, parasites may enter the circulation and travel to various organs causing severe organ diseases such as liver abscesses and cysticercosis. In addition, some larval migration can cause pneumonia and in rare cases hyper infection syndrome with large numbers of larvae being produced and found in every tissue of the body.
- **Red Blood Cells (RBC)** in the stool may be associated with a parasitic or bacterial infection, or an inflammatory bowel condition such as ulcerative colitis. Colorectal cancer, anal fistulas, and hemorrhoids should also be ruled out.
- **White Blood Cells (WBC)** and **Mucus** in the stool can occur with bacterial and parasitic infections, with mucosal irritation, and inflammatory bowel diseases such as Crohn's disease or ulcerative colitis
- **Muscle fibers** in the stool are an indicator of incomplete digestion. Bloating, flatulence, feelings of "fullness" may be associated with increase in muscle fibers.
- **Vegetable fibers** in the stool may be indicative of inadequate chewing, or eating "on the run".







Order: 999999-9999



Client #: 999999

Doctor: Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

Patient: Sample Patient

Id: 999999

Age: 32 DOB:

Sex: Female

Sample Collection

Date/Time

Date Collected

01/11/2023

Date Received

01/13/2023

Date Reported

01/23/2023

Specimens Collected

3

Pathogenic Bacteria	Result	Reference Interval				
		NG	1+	2+	3+	4+
<i>Aeromonas</i> spp.	NG	▲				
<i>Edwardsiella tarda</i>	NG	▲				
<i>Plesiomonas shigelloides</i>	NG	▲				
<i>Salmonella</i> group	NG	▲				
<i>Shigella</i> group	NG	▲				
<i>Vibrio cholerae</i>	NG	▲				
<i>Vibrio</i> spp.	NG	▲				
<i>Yersinia</i> spp.	NG	▲				

Imbalance Bacteria	Result	Reference Interval				
		NG	1+	2+	3+	4+
<i>Lactococcus lactis</i>	4+					▲
<i>Streptococcus parasanguinis</i>	3+				▲	
<i>Streptococcus salivarius/</i> <i>vestibularis</i>	4+					▲

Dysbiotic Bacteria	Result	Reference Interval				
		NG	1+	2+	3+	4+
<i>Citrobacter freundii</i> complex	3+				▲	
<i>Enterobacter cloacae</i> complex	3+				▲	
<i>Klebsiella pneumoniae</i>	3+				▲	

Yeast	Result	Reference Interval				
		NG	1+	2+	3+	4+
<i>Candida intermedia</i>	1+		▲			
<i>Candida krusei</i>	1+		▲			
<i>Candida lusitanae</i>	2+			▲		

**GI 360 Microbiology Information:**

- **Pathogenic bacteria** consist of known pathogenic bacteria that can cause disease in the GI tract. They are present due to the consumption of contaminated food or water, exposure to animals, fish, or amphibians known to harbor the organism. These organisms can be detected by either Multiplex PCR or microbiology culture.
- **Imbalanced bacteria** are usually neither pathogenic nor beneficial to the host GI tract. Imbalances can occur when there are insufficient levels of beneficial bacteria and increased levels of commensal bacteria. Certain commensal bacteria are reported as dysbiotic at higher levels.
- **Dysbiotic bacteria** consist of those bacteria that have the potential to cause disease in the GI tract. They can be present due to a number of factors including: exposure to chemicals that are toxic to beneficial bacteria; the use of antibiotics, oral contraceptives or other medications; poor fiber intake and high stress levels.

Notes:  
NG = No Growth  
Methodology: Culture and identification by MALDI-TOF and conventional biochemicals





**Order:** 999999-9999



**Client #:** 999999

**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

**Patient:** Sample Patient

**Id:** 999999

**Age:** 32 **DOB:**

**Sex:** Female

**Sample Collection**

**Date/Time**

**Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**

01/23/2023

**Specimens Collected** 3



**Microbiology Information:**

- **Yeast** may normally be present in small quantities on the skin, in the mouth and intestine. While small quantities of yeast may be normal, yeast observed in higher quantities is considered abnormal.





**Order:** 999999-9999



**Client #:** 999999

**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

**Patient:** Sample Patient

**Id:** 999999

**Age:** 32 **DOB:**

**Sex:** Female

**Sample Collection**

**Date/Time**

**Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**

01/23/2023

**Specimens Collected**

3

Digestion / Absorption	Result	Unit	L	WRI	H	Reference Interval
Elastase	>500	µg/g				> 200
Fat Stain	None					None – Moderate
Carbohydrates <sup>†</sup>	Negative					Negative
Inflammation	Result	Unit	L	WRI	H	Reference Interval
Lactoferrin	2.0	µg/mL				< 7.3
Lysozyme*	350	ng/mL				≤ 500
Calprotectin	16	µg/g				< 80
Immunology	Result	Unit	L	WRI	H	Reference Interval
Secretory IgA*	120	mg/dL				30 – 275
Short Chain Fatty Acids	Result	Unit	L	WRI	H	Reference Interval
% Acetate <sup>‡</sup>	71	%				50 – 72
% Propionate <sup>‡</sup>	14	%				11 – 25
% Butyrate <sup>‡</sup>	14	%				11 – 32
% Valerate <sup>‡</sup>	0.9	%				0.8 – 5.0
Butyrate <sup>‡</sup>	1.4	mg/mL				0.8 – 4.0
Total SCFA's <sup>‡</sup>	10	mg/mL				5.0 – 16.0
Intestinal Health Markers	Result	Unit	L	WRI	H	Reference Interval
pH	6.5					5.8 – 7.0
β-glucuronidase*	4270	U/h*g				4000 – 9400
Occult Blood	Negative					Negative



## Chemistry Information:

- **Elastase** findings can be used for assessing pancreatic exocrine function and insufficiency.

### Notes:

RI= Reference Interval, L (blue)= Low (below RI), WRI (green)= within RI, Yellow= moderately outside RI, L or H, H (red)= High (above RI)

\*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.

†This test has been modified from the manufacturer's instructions and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements.

‡This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use.

Methodology: Turbidimetric immunoassay, Microscopy, Colorimetric, Elisa, Gas Chromatography, pH Electrode, Enzymatic, Guaiac



**Order:** 999999-9999



**Client #:** 999999

**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

**Patient:** Sample Patient

**Id:** 999999

**Age:** 32 **DOB:**

**Sex:** Female

**Sample Collection**

**Date/Time**

**Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**

01/23/2023

**Specimens Collected**

3



## Chemistry Information:

- **Fat Stain:** Microscopic determination of fecal fat using Sudan IV staining is a qualitative procedure utilized to assess fat absorption and to detect steatorrhea.
- **Carbohydrates:** The presence of reducing substances in stool specimens can indicate carbohydrate malabsorption.
- **Lactoferrin** and **Calprotectin** are reliable markers for differentiating organic inflammation (IBD) from function symptoms (IBS) and for management of IBD. Monitoring levels of fecal lactoferrin and calprotectin can play an essential role in determining the effectiveness of therapy, are good predictors of IBD remission, and can indicate a low risk of relapse.
- **Lysozyme** is an enzyme secreted at the site of inflammation in the GI tract and elevated levels have been identified in IBD patients.
- **Secretory IgA (sIgA)** is secreted by mucosal tissue and represents the first line of defense of the GI mucosa and is central to the normal function of the GI tract as an immune barrier. Elevated levels of sIgA have been associated with an upregulated immune response.
- **Short chain fatty acids (SCFAs):** SCFAs are the end product of the bacterial fermentation process of dietary fiber by beneficial flora in the gut and play an important role in the health of the GI as well as protecting against intestinal dysbiosis. Lactobacilli and bifidobacteria produce large amounts of short chain fatty acids, which decrease the pH of the intestines and therefore make the environment unsuitable for pathogens, including bacteria and yeast. Studies have shown that SCFAs have numerous implications in maintaining gut physiology. SCFAs decrease inflammation, stimulate healing, and contribute to normal cell metabolism and differentiation. Levels of **Butyrate** and **Total SCFA** in mg/mL are important for assessing overall SCFA production, and are reflective of beneficial flora levels and/or adequate fiber intake.
- **pH:** Fecal pH is largely dependent on the fermentation of fiber by the beneficial flora of the gut.
- **Occult blood:** A positive occult blood indicates the presence of free hemoglobin found in the stool, which is released when red blood cells are lysed.
- **β-glucuronidase** is an enzyme that breaks the tight bond between glucuronic acid and toxins in the intestines. The binding of toxins in the gut is protective by way of blocking their absorption and facilitating excretion.





**Order:** 999999-9999



**Client #:** 999999

**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

**Patient:** Sample Patient

**Id:** 999999

**Age:** 32 **DOB:**

**Sex:** Female

**Sample Collection**

**Date/Time**

**Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**

01/23/2023

**Specimens Collected**

3

## Citrobacter freundii complex

### Natural Agents



### Prescriptive Agents

	Resistant	Intermediate	Susceptible
Amoxicillin-Clavulanic Acid	<input checked="" type="checkbox"/>		
Ampicillin	<input checked="" type="checkbox"/>		
Cefazolin	<input checked="" type="checkbox"/>		
Ceftazidime			<input checked="" type="checkbox"/>
Ciprofloxacin			<input checked="" type="checkbox"/>
Sulfamethoxazole / Trimethoprim			<input checked="" type="checkbox"/>



### Susceptibility Information:

- Natural antibacterial** agents may be useful for treatment of patients when organisms display in-vitro sensitivity to these agents. The test is performed by using standardized techniques and filter paper disks impregnated with the listed agent. Relative sensitivity is reported for each natural agent based upon the diameter of the zone of inhibition surrounding the disk. Data based on over 5000 individual observations were used to relate the zone size to the activity level of the agent. A scale of relative sensitivity is defined for the natural agents tested.
- Susceptible** results imply that an infection due to the bacteria may be appropriately treated when the recommended dosage of the tested antimicrobial agent is used. **Intermediate** results imply that response rates may be lower than for susceptible bacteria when the tested antimicrobial agent is used. **Resistant** results imply that the bacteria will not be inhibited by normal dosage levels of the tested antimicrobial agent.

### Notes:

\*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.





**Order:** 999999-9999



**Client #:** 999999

**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

**Patient:** Sample Patient

**Id:** 999999

**Age:** 32 **DOB:**

**Sex:** Female

**Sample Collection**

**Date/Time**

**Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**

01/23/2023

**Specimens Collected**

3

## Enterobacter cloacae complex

### Natural Agents



### Prescriptive Agents

	Resistant	Intermediate	Susceptible
Amoxicillin-Clavulanic Acid	<input checked="" type="checkbox"/>		
Ampicillin	<input checked="" type="checkbox"/>		
Cefazolin	<input checked="" type="checkbox"/>		
Ceftazidime			<input checked="" type="checkbox"/>
Ciprofloxacin			<input checked="" type="checkbox"/>
Sulfamethoxazole / Trimethoprim			<input checked="" type="checkbox"/>



### Susceptibility Information:

- Natural antibacterial** agents may be useful for treatment of patients when organisms display in-vitro sensitivity to these agents. The test is performed by using standardized techniques and filter paper disks impregnated with the listed agent. Relative sensitivity is reported for each natural agent based upon the diameter of the zone of inhibition surrounding the disk. Data based on over 5000 individual observations were used to relate the zone size to the activity level of the agent. A scale of relative sensitivity is defined for the natural agents tested.
- Susceptible** results imply that an infection due to the bacteria may be appropriately treated when the recommended dosage of the tested antimicrobial agent is used. **Intermediate** results imply that response rates may be lower than for susceptible bacteria when the tested antimicrobial agent is used. **Resistant** results imply that the bacteria will not be inhibited by normal dosage levels of the tested antimicrobial agent.

### Notes:

\*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.





**Order:** 999999-9999



**Client #:** 999999

**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

**Patient:** Sample Patient

**Id:** 999999

**Age:** 32 **DOB:**

**Sex:** Female

**Sample Collection**

**Date/Time**

**Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**

01/23/2023

**Specimens Collected**


3

## Klebsiella pneumoniae

### Natural Agents



### Prescriptive Agents



### Susceptibility Information:

- Natural antibacterial** agents may be useful for treatment of patients when organisms display in-vitro sensitivity to these agents. The test is performed by using standardized techniques and filter paper disks impregnated with the listed agent. Relative sensitivity is reported for each natural agent based upon the diameter of the zone of inhibition surrounding the disk. Data based on over 5000 individual observations were used to relate the zone size to the activity level of the agent. A scale of relative sensitivity is defined for the natural agents tested.
- Susceptible** results imply that an infection due to the bacteria may be appropriately treated when the recommended dosage of the tested antimicrobial agent is used. **Intermediate** results imply that response rates may be lower than for susceptible bacteria when the tested antimicrobial agent is used. **Resistant** results imply that the bacteria will not be inhibited by normal dosage levels of the tested antimicrobial agent.

### Notes:

\*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.





**Order:** 999999-9999



**Client #:** 999999

**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

**Patient:** Sample Patient

**Id:** 999999

**Age:** 32 **DOB:**

**Sex:** Female

**Sample Collection**

**Date/Time**

**Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**


01/23/2023

**Specimens Collected**

3

## Candida lusitanae


### Natural Agents



### Non-Absorbed Antifungals



### Azole Antifungals



## Susceptibility Information:

- Natural antifungal** agents may be useful for treatment of patients when organisms display in-vitro susceptibility to these agents. The test is performed by using standardized techniques and filter paper disks impregnated with the listed agent. Relative activity is reported for each natural agent based upon the diameter of the zone of inhibition or no growth zone surrounding the disk. Data based on over 5000 individual observations were used to relate the zone size to the activity level of the agent. A scale of relative activity is defined for the natural agents tested.
- Non-absorbed antifungals** may be useful for treatment of patients when organisms display in-vitro susceptibility to these agents. The test is performed using standardized commercially prepared disks impregnated with Nystatin. Relative activity is reported based upon the diameter of the zone of inhibition or no growth zone surrounding the disk.
- Susceptible** results imply that an infection due to the fungus may be appropriately treated when the recommended dosage of the tested antifungal agent is used. **Susceptible - Dose Dependent (S-DD)** results imply that an infection due to the fungus may be treated when the highest recommended dosage of the tested antifungal agent is used. **Resistant** results imply that the fungus will not be inhibited by normal dosage levels of the tested antifungal agent.

### Notes:

\*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.





**Order:** 999999-9999**Client #:** 999999**Doctor:** Sample Doctor, MD

Doctors Data Inc

123 Main St.

St. Charles, IL 60174 USA

**Patient:** Sample Patient**Id:** 999999**Age:** 32 **DOB:****Sex:** Female**Sample Collection****Date/Time****Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**

01/23/2023

**Specimens Collected**

3

## Introduction

This analysis of the stool specimen provides fundamental information about the overall gastrointestinal health of the patient. When abnormal microflora or significant aberrations in intestinal health markers are detected, specific commentaries are presented. If no significant abnormalities are found, commentaries are not presented.

## Microbiome Abundance Information

### Actinobacteria (phylum)

Actinobacteria is one of the largest bacterial phyla, comprised of Gram-positive bacteria. This phylum includes a wide range of species, with different morphological and physiological characteristics. Significant groups in the human colon include Actinomycetales and Bifidobacteriales. Actinomycetales were inversely associated with clinically significant depression in IBS patients, suggesting these bacteria may be depleted in depressed IBS patients. A strict vegetarian diet may increase the total count of *Actinomyces* spp. compared to following a Western diet.

#### ↓ Actinomycetales (order)

Actinomycetales are considered low abundance colonizers of the gastrointestinal tract with primary residence on the skin. Intake of proton-pump inhibitor drugs has been shown to increase the abundance of Actinomycetales in the gut, possibly by reducing gastric acidity and enabling intestinal colonization by oral microbes. Actinomycetales may be depleted in depressed irritable bowel syndrome patients. The abundance of *Actinomyces* spp. was shown to be higher with a strict vegetarian diet compared to a common Western diet.

### Bacteroidetes (phylum)

Bacteroidetes make up approximately 28% of the gut microbiota in healthy human adults. They are early colonizers of the infant gut and are amongst the most stable, at a species and strain level, in the host. A low preponderance of Bacteroidetes in relation to Firmicutes has been associated with obesity, though this can increase with weight loss and restricted calorie intake.

#### ↓ Bacteroides pectinophilus (species)

*Bacteroides pectinophilus* contributes to breakdown of dietary pectins which are prebiotics. Pectins are complex, plant-derived carbohydrates that are indigestible by human enzymes, but can be easily degraded by certain commensal bacteria in the gut. Subsequent microbial fermentation of constituent sugar moieties yields important short chain fatty acids and other metabolites. The pectin-derived microbial fermentation products have important functions including reduction of ammonia, delay of gastric emptying and postprandial glucose regulation, induction of gut immunity, and maintenance of the mucosal barrier. Adequate intake and microbial metabolism of pectins appears to stimulate growth of various beneficial bacteria, including *Lachnospiraceae*, *Dorea* species, *Bifidobacterium*, *Lactobacillus* species, *Faecalibacterium prausnitzii*, and *Eubacterium rectale*. The abundance of *B. pectinophilus* has been positively correlated with a healthy fasting serum lipid profile, and negatively correlated with biomarkers of for insulin resistance and dyslipidemia. *B. pectinophilus* was less abundant for IBS patients compared to healthy controls. High consumption of kimchi (fermented cabbage) may be associated with lower than normal levels of *B. pectinophilus*.

#### ↓ Bacteroides (species)

Species in the genus *Bacteroides* carry out broad metabolic functions, including degradation of complex plant polysaccharides, proteolytic activities, de-conjugation of bile acids, mucosal barrier integrity, short chain fatty acid production, fatty acid storage and glucose metabolism. *Bacteroides* spp. are maintained at a higher abundance in breastfed individuals into adulthood. *Bacteroides fragilis* plays an important role in the prevention of intestinal inflammation. An energy-restricted diet has been shown to increase *B. fragilis* in overweight adolescents. An increase in *B. stercoris* has been associated with higher risk of colon cancer. Decreased levels of *Bacteroides* spp. have been reported in association with multiple sclerosis, rheumatoid arthritis and Parkinson's disease.

### Firmicutes (phylum)

The phylum Firmicutes constitutes the most diverse and abundant group of gastrointestinal microbiota which are grouped into four classes, Bacilli, Clostridia, Erysipelotrichia, and Negativicutes. They constitute about 39% of gut bacteria in healthy adults, but may increase to as high as 80% in an imbalanced microbial community.

**Order:** 999999-9999**Client #:** 999999**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA**Patient:** Sample Patient**Id:** 999999**Age:** 32 **DOB:****Sex:** Female**Sample Collection****Date/Time****Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**

01/23/2023

**Specimens Collected**

3

### Microbiome Abundance Information continued...

#### ↓ Firmicutes

High Firmicutes and low Bacteroidetes abundances have been equivocally associated with obesity. A high-fat diet is associated higher abundance of both Firmicutes and Proteobacteria, and lower abundance of Bacteroidetes in mice. Low abundance of Firmicutes and greater abundance of *Akkermansia muciniphila* have been reported in lean individuals. Increased levels of Firmicutes have been associated with Crohn's disease and ulcerative colitis.

#### ↓ Dorea (genus)

*Dorea* is a genus within the *Lachnospiraceae* family that is in the Firmicutes phylum. *Dorea* species are known to produce hydrogen and carbon dioxide as end-products of glucose fermentation and may be associated with bloating. Decreased levels of *Dorea* spp. were observed in patients with Parkinson's disease. Recent studies have identified increased levels of *Dorea* spp. in patients diagnosed with IBS, nonalcoholic fatty liver disease and non-alcoholic steatohepatitis, multiple sclerosis and colorectal cancer.

#### ↓ Eubacterium hallii (species)

*Eubacterium hallii* and *Eubacterium rectale* are both part of the *Lachnospiraceae* family that is in the Firmicutes phylum. *E. hallii* and *E. rectale* produce butyrate that is a key regulator of mucosal barrier integrity and function. Decreased levels of *Eubacterium* spp. have been associated with very high protein diets. *Eubacterium hallii* is capable of metabolizing glucose into products with antimicrobial properties.

#### ↓ Lactobacillus (genus)

Decreased and normal levels of *Lactobacillus* spp. have been reported in patients with irritable bowel syndrome. *Lactobacillus* spp. abundance was shown to be lower in the active phase of ulcerative colitis. *Lactobacillus* levels were shown to be increased after inulin consumption, but decreased after consumption of maltodextrin. Polyphenols derived from chocolate, green tea, blackcurrant, red wine and grape seed extracts have been shown to increase *Lactobacillus* species. The increased abundance of *Lactobacillus* species has been associated with amelioration of inflammation.

#### Proteobacteria (phylum)

Proteobacteria include a wide variety of pathogens, including species within the *Escherichia*, *Shigella*, *Salmonella*, *Vibrio*, and *Helicobacter* genera. The phylum includes a number of species that are permanent residents of the microbiota and capable of inducing nonspecific inflammation and diarrhea when their presence is increased. Proteobacteria make up approximately 2% of the gut microbiota in healthy adults.

#### ↑ Enterobacteriaceae (family)

*Enterobacteriaceae* is a large family of bacteria within the Proteobacteria phyla. *Enterobacteriaceae* is inclusive of normal commensal species, harmless opportunists, and many of the more familiar pathogens, such as *Salmonella*, *Escherichia coli*, *Klebsiella*, *Shigella* and *Proteus*. Other potential disease-causing bacteria in this family include *Enterobacter* and *Citrobacter* species. The abundance of Proteobacteria, which are generally pro-inflammatory, is presented on the white shadowed web plot within the hexagonal diagram. The presence of specific dysbiotic and pathogenic *Enterobacteriaceae* bacteria, if detected by PCR or culture, are reported in the Gastrointestinal Pathogens and Microbiology sections of this report.

Overall, *Enterobacteriaceae* were found at higher levels in patients with NAFLD and PD. Diets rich in complex carbohydrates are associated with lower levels of *Enterobacteriaceae*, in comparison to diets rich in fat and/or protein.

#### Tenericutes (phylum)

Tenericutes are cell wall-less bacteria that do not synthesize precursors of peptidoglycan. Tenericutes consist of four main clades designated as the *Acholeplasma*, *Spiroplasma*, *Pneumoniae* and *Hominis* clusters. Tenericutes are typically parasites or commensals of eukaryotic hosts.

#### Verrucomicrobia (phylum)

Verrucomicrobia is a less common phylum in the human gut microbiota, but one with increasing recognition with regards to health. Verrucomicrobia includes *Akkermansia muciniphila*. The obligate anaerobe *A. muciniphila* constitutes 3-5% of total bacteria in a healthy microbiome, and has a protective or anti-inflammatory role in the intestinal mucosa.



**Order:** 999999-9999



**Client #:** 999999

**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

**Patient:** Sample Patient

**Id:** 999999

**Age:** 32 **DOB:**

**Sex:** Female

**Sample Collection**

**Date/Time**

**Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**

01/23/2023

**Specimens Collected**

3

## GI Pathogens

### Introduction

The GI Pathogen profile is performed using an FDA-cleared multiplex PCR system. It should be noted that PCR testing is much more sensitive than traditional techniques and allows for the detection of extremely low numbers of pathogens. PCR testing does not differentiate between viable and non-viable pathogens and should not be repeated until 21 days after completion of treatment or resolution to prevent false positives due to lingering traces of DNA. PCR testing can detect multiple pathogens in the patient's stool but does not differentiate the causative pathogen. All decisions regarding the need for treatment should take the patient's complete clinical history and presentation into account.

## Microbiology

### Pathogenic/Dysbiotic Flora

In a healthy balanced state of intestinal flora, the beneficial bacteria make up a significant proportion of the total microflora. However, in many individuals there is an imbalance or deficiency of beneficial flora (insufficiency dysbiosis) and an overgrowth of non-beneficial (imbalance) or even pathogenic microorganisms. This can be due to a number of factors including: consumption of contaminated water or food; daily exposure of chemicals that are toxic to beneficial bacteria; the use of antibiotics, oral contraceptives or other medications; poor fiber intake and high stress levels.

A number of toxic substances can be produced by the dysbiotic bacteria including amines, ammonia, hydrogen sulfide, phenols, and secondary bile acids which may cause inflammation or damage to the brush border of the intestinal lining. If left unchecked, long-term damage to the intestinal lining may result in leaky gut syndrome, allergies, autoimmune disease (e.g. rheumatoid arthritis), irritable bowel syndrome, fatigue, chronic headaches, and sensitivities to a variety of foods. In addition, pathogenic bacteria can cause acute symptoms such as abdominal pain, nausea, diarrhea, vomiting, and fever in cases of food poisoning.

Bacterial sensitivities to a variety of prescriptive and natural agents have been provided for the pathogenic bacteria that were cultured from this patient's specimen. This provides the practitioner with useful information to help plan an appropriate treatment regimen. Supplementation with probiotics or consumption of foods (yogurt, kefir, miso, tempeh, tamari sauce) containing strains of lactobacilli, bifidobacteria, and enterococci may help restore healthy flora levels. Soluble fiber and polyphenols derived from chocolate, green tea, blackcurrant, red wine and grape seed extracts have been found to increase the numbers of beneficial bacteria. Hypochlorhydria may also predispose an individual to bacterial overgrowth, particularly in the small intestine. Nutritional anti-inflammatories can aid in reversing irritation to the GI lining. These include quercetin, vitamin C, curcumin, gamma-linoleic acid, omega-3 fatty acids (EPA, DHA), and aloe vera. Other nutrients such as zinc, beta-carotene, pantothenic acid, and L-glutamine provide support for regeneration of the GI mucosa. A comprehensive program may be helpful in individuals in whom a dysbiotic condition has caused extensive GI damage.

### *Citrobacter* spp

*Citrobacter* spp., a gram-negative bacterium and member of the *Enterobacteriaceae* family, is considered dysbiotic at 3+ or greater. *Citrobacter freundii* complex (including *C. freundii*, *C. braakii*, *C. gullenii*, *C. murliniae*, *rodentium*, *C. wermanii*, *C. youngae*), *C. koseri* and *C. farmeri*, can cause diarrheal disease. Symptoms are the result of an *E. coli*-like heat-stable enterotoxin and hydrogen sulfide. *Citrobacter freundii* complex has been implicated as a cause of gastrointestinal infection and inflammation, acute dysentery, and dyspepsia. Acute symptoms can include profuse, watery diarrhea without abdominal pain, fecal blood, or white blood cells.

*Citrobacter* spp. thrive on fructooligosaccharides (FOS), a common ingredient in artificial or alternative sweetener.

Antibiotics may be indicated if symptoms are prolonged. Refer to the antimicrobial susceptibilities to identify the most appropriate agent.

### *Enterobacter cloacae* complex

*Enterobacter cloacae* complex is part of the *Enterobacteriaceae* family. *E. cloacae* complex is a group of six closely related species with similar resistance patterns: *E. cloacae*, *E. asburiae*, *E. hormaechei*, *E. kobei*, *E. ludwigii*, and *E. nimipressuralis*. This gram-negative bacterium is considered dysbiotic at levels of 3+ or greater. *E. cloacae* complex is considered an opportunistic pathogen associated with diarrhea in children. A Shiga-like toxin-producing *E. cloacae* was isolated from the feces of an infant with hemolytic-uremic syndrome. However, *E. cloacae* complex is most often involved in extraintestinal infections including the urinary tract, respiratory tract, and cutaneous wounds.

**Order:** 999999-9999**Client #:** 999999**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA**Patient:** Sample Patient**Id:** 999999**Age:** 32 **DOB:****Sex:** Female**Sample Collection****Date/Time****Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**

01/23/2023

**Specimens Collected**

3

### Microbiology continued...

Widely distributed in the environment, *Enterobacter* spp. is commonly isolated from both human and animal feces. Environmental strains of *Enterobacter* spp. are capable of growth in foods at refrigeration temperature.

*E. cloacae* complex is known to possess inducible  $\beta$ -lactamases. Isolates may become resistant to all cephalosporins after initiation of therapy. Avoid  $\beta$ -lactam-inhibitor drugs such as amoxicillin/ clavulanate, ampicillin/sulbactam, and piperacillin/tazobactam.

Antibiotics may be indicated in systemic infections if symptoms are prolonged. Refer to the antimicrobial susceptibilities for treatment.

#### ***Klebsiella* spp**

*Klebsiella* spp. are gram-negative bacilli belonging to the *Enterobacteriaceae* family and closely related to the genera *Enterobacter* and *Serratia*. *Klebsiella* spp. are considered dysbiotic in the amount of 3 - 4 +. *Klebsiella* spp. are widely distributed in nature and in the gastrointestinal tract of humans. In humans, they may colonize the skin, oral cavity, pharynx, or gastrointestinal tract. Regarded as normal flora in many parts of the colon, intestinal tract and biliary tract, the gut is the main reservoir of opportunistic strains. This bacteria has the potential to cause intestinal, lung, urinary tract, and wound infections, but overgrowth of *Klebsiella* spp. is commonly asymptomatic. *K. pneumoniae*, in particular, may cause diarrhea and some strains are enterotoxigenic. Infection has been linked to ankylosing spondylitis as well as myasthenia gravis (antigenic cross-reactivity), and these patients usually carry larger numbers of the organism in their intestines than healthy individuals. *Klebsiella oxytoca* causes antibiotic associated hemorrhagic colitis. These strains have been shown to produce a cytotoxin that is capable of inducing cell death in various epithelial-cell cultures.

*Klebsiella* is a significant nosocomial infectious agent, partially due to the ability of organisms to spread rapidly. *Klebsiella* accounts for approximately 3-7% of all hospital-acquired infections, placing it among the top eight pathogens in hospitals. Extraintestinal infection typically involves the respiratory or urinary tracts, but may infect other areas such as the biliary tract and surgical wound sites. *K. pneumoniae* and *K. oxytoca* are the two members of this genus responsible for most extraintestinal human infections.

Treatment of these organisms has become a major problem because of resistance to multiple antibiotics and potential transfer of plasmids to other organisms. Proper hand washing is crucial to prevent transmission from patient to patient via medical personnel. Contact isolation should be used for patients colonized or infected with highly antibiotic-resistant *Klebsiella* strains. *Klebsiella ozaenae* and *Klebsiella rhinoscleromatis* are infrequent isolates that are subspecies of *K. pneumoniae*; however, each is associated with a unique spectrum of disease. *K. ozaenae* is associated with atrophic rhinitis, a condition called ozena, and purulent infections of the nasal mucous membranes. *K. rhinoscleromatis* causes the granulomatous disease rhinoscleroma, an infection of the respiratory mucosa, oropharynx, nose, and paranasal sinuses.

Antibiotics may be indicated if symptoms are prolonged and in systemic infections. Refer to the antimicrobial susceptibilities for treatment.

#### **Imbalanced Flora**

Imbalanced flora are those bacteria that reside in the host gastrointestinal tract and neither injure nor benefit the host. Certain dysbiotic bacteria may appear under the imbalanced category if found at low levels because they are not likely pathogenic at the levels detected. Imbalanced bacteria are commonly more abundant in association with insufficiency dysbiosis, and/or a fecal pH more towards the alkaline end of the reference range (5.8 - 7.0). Treatment with antimicrobial agents is unnecessary unless bacteria appear under the dysbiotic category.

#### **Cultured Yeast**

Small amounts of yeast (+1) may be present in a healthy GI tract. However higher levels of yeast (> +1) are considered to be dysbiotic. A positive yeast culture and sensitivity to prescriptive and natural agents may help guide decisions regarding potential therapeutic intervention for yeast overgrowth. When investigating the presence of yeast, disparity may exist between culturing and microscopic examination. Yeast grows in colonies and is typically not uniformly dispersed throughout the stool. Further, some yeast may not survive transit through the intestines rendering it unviable for culturing. This may lead to undetectable or low levels of yeast identified by culture, despite a significant amount of yeast visualized microscopically. Therefore, both microscopic examination and culture are helpful in determining if abnormally high levels of yeast are present.



**Order:** 999999-9999



**Client #:** 999999

**Doctor:** Sample Doctor, MD  
Doctors Data Inc  
123 Main St.  
St. Charles, IL 60174 USA

**Patient:** Sample Patient

**Id:** 999999

**Age:** 32 **DOB:**

**Sex:** Female

**Sample Collection**

**Date/Time**

**Date Collected**

01/11/2023

**Date Received**

01/13/2023

**Date Reported**

01/23/2023

**Specimens Collected** 3

**Microbiology continued...**

**Dysbiotic Yeast**

Yeast was cultured from this stool specimen at a level that is considered to be dysbiotic. A positive yeast culture and sensitivity to prescriptive and natural agents may help guide decisions regarding potential therapeutic intervention for chronic yeast syndrome. When investigating the presence of yeast, disparity may exist between culturing and microscopic examination. Yeast grows in colonies and is typically not uniformly dispersed throughout the stool. This may lead to undetectable or low levels of yeast identified by culture, despite a significant amount of yeast visualized microscopically.